Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kestra Medical Technologies (KMTS) Net Cash Flow (2024 - 2026)

Kestra Medical Technologies (KMTS) reported Net Cash Flow of $115.9 million for Q1 2026, up 613.59% year-over-year from $16.2 million in Q1 2025, and up 549.39% on a QoQ basis from -$25.8 million in Q4 2025.

Kestra Medical Technologies (KMTS) has 3 years of Net Cash Flow data on file, last reported at $115.9 million in Q1 2026.

  • Quarterly Net Cash Flow rose 613.59% year-over-year to $115.9 million in Q1 2026, while the trailing twelve-month figure through Jan 2026 was $237.0 million (up 504.02% YoY) and the FY2025 annual result came in at $229.3 million, up 3503.26% from the prior year.
  • Net Cash Flow rose to $115.9 million in Q1 2026 per KMTS's latest filing, from -$25.8 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $183.2 million in Q2 2025 and bottomed at -$36.4 million in Q3 2025.
  • The 3-year median for Net Cash Flow is -$14.7 million (2024), against an average of $34.5 million.
  • Peak annual rise in Net Cash Flow reached 2766.9% in 2025, while the deepest fall reached 139.67% in 2025.
  • Tracing KMTS's Net Cash Flow over 3 years: stood at -$23.1 million in 2024, then retreated by 11.88% to -$25.8 million in 2025, then surged by 549.39% to $115.9 million in 2026.
  • Per Business Quant, the three latest KMTS Net Cash Flow figures stand at $115.9 million (Q1 2026), -$25.8 million (Q4 2025), and -$36.4 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Cash Flow (Qtr)
1 Intuitive Surgical 156.17 Bn 151.78 Bn 1.83 Bn -1.36 Bn
2 Becton Dickinson 41.51 Bn 40.49 Bn 2.15 Bn 118.00 Mn
3 Resmed 30.43 Bn 28.77 Bn 890.98 Mn 240.86 Mn
4 West Pharmaceutical Services 22.78 Bn 22.26 Bn 296.40 Mn -261.50 Mn
5 Solventum 13.39 Bn 13.39 Bn 1.10 Bn -316.00 Mn
6 Cooper Companies 12.33 Bn 12.20 Bn 695.20 Mn 10.10 Mn
7 Align Technology 11.65 Bn 10.59 Bn 736.59 Mn -28.67 Mn
8 Baxter International 9.81 Bn 7.77 Bn 891.00 Mn 69.00 Mn
9 Aptargroup 7.39 Bn 7.19 Bn 351.91 Mn -176.75 Mn
10 Kestra Medical Technologies 1.13 Bn 840.05 Mn 12.91 Mn 115.90 Mn

Historic Data

Download Data 🔒
DateValue
Jan 31, 2026 115.90 Mn
Jan 31, 2026 115.90 Mn
Oct 31, 2025 -25.79 Mn
Oct 31, 2025 -25.79 Mn
Jul 31, 2025 -36.38 Mn
Jul 31, 2025 -36.38 Mn
Apr 30, 2025 183.24 Mn
Apr 30, 2025 183.24 Mn
Jan 31, 2025 -22.57 Mn
Jan 31, 2025 -22.57 Mn
Oct 31, 2024 -23.05 Mn
Oct 31, 2024 -23.05 Mn
Jul 31, 2024 91.72 Mn
Jul 31, 2024 91.72 Mn
Apr 30, 2024 -6.87 Mn
Apr 30, 2024 -6.87 Mn